Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands, € in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Cash flows from operating activities:
Net income	$ 4,858	$ 4,163
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,016	2,069
Gain on disposal of property, plant & equipment	(12)	0
Share-based compensation	692	501
Interest expense on finance leases	1	1
Deferred income taxes	(440)	279
Changes in operating assets and liabilities:
Receivables, net	(4,467)	(3,590)
Inventories	(7,826)	(1,374)
Prepaid expenses and other current assets	(1,712)	(70)
Other assets	308	(219)
Accounts payable	4,105	1,656
Accrued expenses	(3,366)	(1,083)
Deferred revenue	793	(124)
Income taxes payable	1,130	847
Non-qualified deferred compensation plan and other liabilities	(296)	278
Net cash (used in) provided by operating activities	(3,216)	3,334
Cash flows from investing activities:
Additions to property, plant, and equipment	(2,334)	(1,449)
Proceeds from sale of fixed assets	12	0
Net cash used in investing activities	(22,975)	(1,449)
Cash flows from financing activities:
Proceeds from advances on revolving line of credit	28,000	0
Payments on revolving line of credit	(7,000)	0
Principal payments of long-term debt	(1,000)	0
Principal payments on finance lease obligations	(16)	(4)
Payment of statutory withholdings for restricted stock units vested	(1,299)	(738)
Net cash provided by (used in) financing activities	18,685	(742)
Effect of foreign currency exchange rates on cash and cash equivalents	41	0
Net (decrease) increase in cash and cash equivalents	(7,465)	1,143
Cash and cash equivalents at beginning of period	11,117	24,234
Cash and cash equivalents at end of period	3,652	25,377
Advant Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	(20,768)	0
DAS Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	$ 115	$ 0